Form 4: Nurix Legal Officer Sells Shares for Tax Obligations

Nurix Therapeutics' Chief Legal Officer, Christine Ring, reported the vesting of restricted stock units and a subsequent 'sell to cover' transaction for tax withholding purposes.

Summary

• Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), reported transactions on October 30, 2025.
• Acquired a total of 10,532 shares of common stock through the vesting of Restricted Stock Units (RSUs) at an exercise price of $0.
• Disposed of 3,644 shares of common stock at a weighted average sale price of $12.7967.
• The sales were non-discretionary, mandated by Nurix Therapeutics' equity incentive plans to cover tax withholding obligations related to RSU vesting.
• Beneficial ownership of common stock following these reported transactions is 50,897 shares.

Sentiment

Score: 6

Explanation: The filing reports routine vesting of restricted stock units and a non-discretionary 'sell to cover' transaction for tax purposes, which is a standard practice for executive equity compensation and does not indicate a change in management's confidence or company fundamentals.

Positives

• The vesting of Restricted Stock Units indicates continued equity compensation for a key executive, aligning their interests with shareholders.
• The reported sale of shares was explicitly stated as a 'sell to cover' transaction for tax withholding, not a discretionary sale by the officer, which typically does not signal a lack of confidence.

Negatives

• A portion of the executive's shares were sold, resulting in a reduction of direct beneficial ownership, even if for tax purposes.

Future Outlook

NA

Management Comments

• It was noted that the sales reported represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

NA

Related Party Transactions

• Vesting of Restricted Stock Units (RSUs) granted to Christine Ring, Chief Legal Officer, as part of her compensation package.
• Sale of shares to cover tax withholding obligations related to RSU vesting, mandated by the Issuer's equity incentive plans.

Stakeholder Impact

• Shareholders: The transaction is a routine event for executive compensation and is unlikely to have a significant impact on the company's share price or long-term value.
• Employees: Reinforces the company's established equity compensation structure for executives.

Next Steps

• Continued vesting of remaining Restricted Stock Units according to their respective schedules, subject to the Reporting Person's provision of services to the Issuer.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the vesting of restricted stock units and a non-discretionary 'sell to cover' sale for tax purposes. It does not indicate any change in the company's fundamentals or management's outlook, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Sale, Chief Legal Officer, Christine Ring, Equity Compensation